Initial chemotherapy dose reductions and subsequent treatment delivery in stage I–IIIA breast cancer

Early dosing decisions shaped subsequent chemotherapy delivery. Most patients who began at full dose maintained consistent dosing, whereas early reductions did not stave off subsequent changes, underscoring the need to balance safety with adequate dose intensity.

Authors

Institutions

Publication Details

Journal
Cancer
Published
2026-02-24
DOI
https://doi.org/10.1002/cncr.70294
Primary Topic
Breast Cancer Treatment Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Initial chemotherapy dose reductions and subsequent treatment delivery in stage I–IIIA breast cancer

Rebecca A. Hubbard, Emily Valice, Jenna Bhimani, Kanichi G. Nakata et al.
Cancer
Breast Cancer Treatment Studies
article

Initial chemotherapy dose reductions and subsequent treatment delivery in stage I–IIIA breast cancer

Rebecca A. Hubbard, Emily Valice, Jenna Bhimani, Kanichi G. Nakata, Rachael P. Burganowski-Doud, Isaac Joshua Ergas, Tatjana Kolevska, Raymond Liu, Sara Tabatabai, Jennifer J. Griggs, Sonia Persaud, Yuriy Kotsurovskyy, Janise M. Roh, Candyce H. Kroenke, Elizabeth D. Kantor, Lu Yang, Yashasvini Sampathkumar, L. Kushi, V. S. Blinder, Kelli O'Connell, Grace B Gallagher, Maria J Monroy-Iglesias, Elisa V Bandera, Cecile A Laurent, Narre Heon
article en

Abstract

Early dosing decisions shaped subsequent chemotherapy delivery. Most patients who began at full dose maintained consistent dosing, whereas early reductions did not stave off subsequent changes, underscoring the need to balance safety with adequate dose intensity.

CancerVol. 132(5)
Rutgers, The State University of New Jersey (US), Memorial Sloan Kettering Cancer Center (US), Kaiser Permanente (US), Kaiser Permanente Washington Health Research Institute (US), University of Michigan (US), Michigan Medicine (US), Kaiser Permanente Vallejo Medical Center (US), Kaiser Permanente San Francisco Medical Center (US), Rutgers Cancer Institute (US)
Good health and well-being
Openalex Percentile: Top 44%
Breast Cancer Treatment Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.